Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Acton takes over US rights to Nasacort HFA from Sanofi US

Executive Summary

Acton Pharmaceuticals Inc. (respiratory therapeutics) has licensed exclusive US rights to Sanofi US’s aerosol nasal allergy treatment Nasacort HFA (triamcinolone acetonide). Financial terms were not disclosed, but Sanofi states that it retains all rights to its already marketed aqueous form Nasacort AQ.
Deal Industry
  • Medical Devices
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Nasal
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing (Licensing)

Related Companies